SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...

There are no well-established re-treatment options for local recurrence after primary curative radiation therapy for prostate cancer (PCa), as prospective studies with long-term follow-up are lacking.

ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

The American Society of Clinical Oncology (ASCO) has endorsed guidelines from the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) on the use of adjuvant and ...

Dear Dr. Roach: I am a healthy 89-year-old United States Army veteran. In August 2017, I was diagnosed with advanced prostate cancer and was treated with Lupron and radiation. These treatments have ...

Once these scans are performed, it is imperative to evaluate the PSA values for a trend. Several studies [3,4] have sought to clarify the impact of rising PSAs based on pretreatment characteristics ...

Please provide your email address to receive an email when new articles are posted on . The American Urological Association released a clinical practice guideline pertaining to salvage therapy for men ...